Point-of-Care 3D Printing of Medical Devices

Key principle: point-of-care (PoC) 3D printing of medical devices requires clear allocation of manufacturing responsibilities, controlled processes and device-specific validation. A resin, printer or material certificate alone does not establish compliance of the finished device.

FDA discussion paper: status and scope

The U.S. FDA published Discussion Paper: 3D Printing Medical Devices at the Point of Care to obtain stakeholder feedback on potential regulatory approaches and manufacturing scenarios. The FDA expressly describes this document as a discussion paper rather than final guidance.

The paper considers issues such as facility capability, quality controls, responsible entities and the concept of a Medical Device Production System (MDPS). These scenarios should therefore be read as part of FDA policy development, not as a blanket authorisation or certification pathway for any resin or PoC workflow.

Why photopolymer workflow control matters

Photopolymer materials change state during printing, washing and post-curing. The final part can therefore differ materially from the liquid resin as supplied. Device manufacturers should define and validate the complete process appropriate to the intended device, including material version, printer, exposure, cleaning, post-curing, finishing, traceability and acceptance criteria.

Product-specific SDS, TDS, IFU and test reports can support this work, but their scope should not be extended beyond the Product/version, test conditions and documented workflow to which they apply.

Raw materials and finished devices

3Dresyns supplies photopolymer resins as manufacturing materials. Whether a specific material or product falls within a medical-device regulatory framework depends on its legal status, intended purpose, jurisdiction and manner of supply. The finished-device legal manufacturer remains responsible for the regulatory assessment and validation applicable to the device it places on the market or otherwise manufactures under the relevant framework.

Current FDA quality-system reference

For U.S. finished device manufacturers, the FDA Quality Management System Regulation (QMSR) became effective on 2 February 2026 and incorporates ISO 13485:2016 by reference within the U.S. device quality-system framework. Applicability depends on the regulated entity and device circumstances.

PoC responsibility models

The FDA discussion paper describes potential PoC scenarios in which responsibilities may differ between a healthcare facility, a traditional manufacturer and an MDPS manufacturer. The practical requirement is to establish, before production, which entity carries the applicable manufacturing and regulatory responsibilities for the specific device and workflow.

Practical controls

define the intended use and responsible legal manufacturer;
select the material and equipment for the intended workflow;
validate printing and post-processing parameters appropriate to the device;
maintain traceability and controlled records;
apply device-appropriate risk management, verification and biological evaluation where relevant;
avoid treating a raw-material statement or certificate as a substitute for finished-device validation.

3Dresyns conclusions about 3D Printing Medical Devices at the Point of Care